Skip to content

D&A at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$4M

Other financials

Income statement

See full
Revenue$2.5B+1.9%
Gross profit$1.8B+0.8%
Operating income$610.7M
Net income$319.5M+32.8%
EPS (diluted)$2.15+31.1%

Balance sheet

See full
Cash & equivalents$3.4B+30.2%
Total debt$6.6B+34.7%
Total equity$18.7B+9.9%
Total assets$29.5B+5.2%

Cash flow

See full
Operating cash flow$645.5M+149%
CapEx$51.2M+38.0%
Free cash flow$594.3M+167%

Valuation

See full
Market cap$31.9B+71.5%
Enterprise value$35.08B+56.4%
P/E22.5×+10.3×
P/S3.2×+1.3×

Profitability

See full
Gross margin75.5%-0.1pp
Operating margin22.9%
Net margin14.3%-0.8pp
FCF margin24.4%-0.4pp

Returns & leverage

See full
Return on equity8%-1.2pp
Debt / equity0.4×+0.1×
Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biogen's D&A?
Biogen (BIIB) reported D&A of $204.4M in Q1 2026.
How has Biogen's D&A changed year-over-year?
Biogen's D&A increased by 11.6% year-over-year, from $183.2M to $204.4M.
What is the long-term trend for Biogen's D&A?
Over 4 years (2021 to 2025), Biogen's D&A has grown at a 12.5% compound annual growth rate (CAGR), from $487.7M to $779.9M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.